Focus:
Cardiovascular
-
26 March 2020 News
AstraZeneca’s Lokelma approved for hyperkalaemia in Japan
The Japanese Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) for patients with hyperkalaemia, characterised by elevated levels of potassium in the blood. Lokelma is...
-
20 March 2020 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
9 March 2020 Comment
Increased recognition of microvascular angina in clinical practice
A proportion of patients with exertional angina and symptoms strongly suggestive of coronary artery disease (CAD) show normal coronary angiograms and are designated as having microvascular angina. Microvascular angina is...
-
20 February 2020 Comment
Pfizer’s Vyndaqel set to achieve blockbuster status in 2021 with EU approval
Pfizer has announced today that its rare disease oral drug Vyndaqel (tafamidis) has gained a new European Medicines Agency (EMA) approval for expanded use in treating adults with wild-type or...
-
19 February 2020 Analysis
AstraZeneca Q&A: combatting shared risk factors in CVRM diseases
Due to links between CV, renal and metabolic disease, AstraZeneca has created a joint cardiovascular, renal and metabolic unit to address unmet needs and shared risk factors across the three...
-
14 February 2020 News
FDA withdraws Eisai’s weight management drug Belviq due to cancer risk
The US Food and Drug Administration (FDA) has requested that Eisai voluntarily withdraw its weight management drug Belviq (lorcaserin) from the US market. Eisai has “submitted a request to voluntarily...
-
7 February 2020 Comment
Esperion’s cholesterol-lowering therapy will offer new option for statin-intolerant patients
On January 31, Esperion Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorisation for...
-
3 February 2020 Comment
Major boost to heart failure market expected
GlobalData expects that the heart failure market will see large growth over 2018–2028, with a Compound Annual Growth Rate (CAGR) of 19.5%. This is due to a large pipeline of...
-
30 January 2020 Comment
US updates guidelines for stress echocardiography use in ischemic heart disease
The American Society of Echocardiography recently re-issued guidelines for the use of stress echocardiography in patients with ischemic heart disease (IHD), also known as coronary artery disease (CAD), last updated...
-
27 January 2020 News
Novo Nordisk’s Saxenda not recommended for NHS use
The UK’s National Institute for Health and Care Excellence (NICE) has decided to not recommend National Health Service (NHS) use of Novo Nordisk’s Saxenda (liraglutide).